Cargando…

P077: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans

Detalles Bibliográficos
Autores principales:	Shakir, Rebecca, Butterworth, Victoria, Ntentas, Georgios, Ramroth, Johanna, Cutter, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Living Beyond Lymphoma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621505/ http://dx.doi.org/10.1097/01.HS9.0000890876.33128.55

Ejemplares similares

P073: Increased risk of colorectal cancer following treatment for Hodgkin lymphoma
por: Geurts, Yvonne M.G., et al.
Publicado: (2022)

P072: Impact of Ageing on the Survivorship Experiences of Patients with Hodgkin Lymphoma
por: Bates, Cherie, et al.
Publicado: (2022)

P067: A pilot of lung cancer screening for survivors of Hodgkin lymphoma
por: Broadbent, Rachel, et al.
Publicado: (2022)

T064: Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors
por: Neppelenbroek, Suzanne I.M., et al.
Publicado: (2022)

P078: Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors
por: Stadtbaeumer, Nele, et al.
Publicado: (2022)

P069: Characterisation of influencing parameters on oocyte quality preservation in a cohort of Hodgkin lymphoma patients
por: Chuzel, Chloé, et al.
Publicado: (2022)

T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
por: Entrop, Joshua P., et al.
Publicado: (2022)

P071: First results of cardiovascular screening in a survivorship care program for Hodgkin lymphoma survivors in the Netherlands
por: Lammers, Eline M.J., et al.
Publicado: (2022)

P074: Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients – A Nationwide Danish Cohort Study
por: Rossetti, Sára, et al.
Publicado: (2022)

P081: Treatment-related circulatory diseases and mortality in Hodgkin lymphoma patients using multi-state modelling and relative survival
por: Baech, Joachim, et al.
Publicado: (2022)

P076: Pneumococcal infection in splenectomised Hodgkin lymphoma patients: Do they pose a problem today and what is the best long-term strategy?
por: Björkholm, Magnus, et al.
Publicado: (2022)

T066: Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study
por: Dinan, Michaela, et al.
Publicado: (2022)

P079: PROCTCAE as a patient-reported outcome measurement (PROM) questionaire in patients with Hodgkin Lymphoma captures different adverse events profile than those reported by physicians
por: Ramos-Cillan, Sergio, et al.
Publicado: (2022)

P068: A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)
por: Marková, Jana, et al.
Publicado: (2022)

P075: My Hodgkin, My Health: Feasibility of a mobile application to collect long term follow up data about Hodgkin patients
por: Kailainathan, Gajan, et al.
Publicado: (2022)

P070: Design of the INSIGHT study, evaluation of long-term follow-up care for lymphoma survivors in the Netherlands: does survivorship care at the BETER clinics reduce morbidity and mortality from late effects of lymphoma treatment and associated costs?
por: Nijdam, Annelies, et al.
Publicado: (2022)

P080: The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment
por: Mieras, Adinda, et al.
Publicado: (2022)

Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry
por: Jones, David A., et al.
Publicado: (2022)

T022: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
por: Shakir, Rebecca, et al.
Publicado: (2022)

Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors
por: Holtzman, Adam L., et al.
Publicado: (2019)

P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
por: Jones, David, et al.
Publicado: (2022)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer
por: Guzhva, Lidia, et al.
Publicado: (2019)

Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?
por: Lee, Jessica W., et al.
Publicado: (2019)

Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma
por: Cutter, David J., et al.
Publicado: (2021)

Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma
por: Pinnix, Chelsea C., et al.
Publicado: (2018)

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy
por: Sheu, Tommy, et al.
Publicado: (2018)

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

The role of motion management and position verification in lymphoma radiotherapy
por: Aznar, Marianne, et al.
Publicado: (2021)

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
por: Taylor, Joseph G., et al.
Publicado: (2022)

B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma
por: Thurner, Lorenz, et al.
Publicado: (2023)

EBV & lymphoma
por: Caballero, Dolores
Publicado: (2019)

Follicular lymphoma
por: Leich, Ellen
Publicado: (2019)

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)

Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies
por: Boot, Max V., et al.
Publicado: (2022)

Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection
por: Ntentas, Georgios, et al.
Publicado: (2022)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway
por: Zhang, Xiao-Yin, et al.
Publicado: (2022)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021)

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors
por: Svoboda, Jakub, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r871p963t7a4utpk0at82cdavc